Non-surgical BCT can be performed using KORTUC II, which has three major characteristics: imaging guidance by ultrasonography; enzyme-targeting of peroxidase/catalase; and targeting of breast cancer stem cells via the CD44 receptor. This evidence concerns the gene CAT and breast carcinoma.